Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$692.0K-97.50%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael S. Exton
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Beta
- 1.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.72
Financials
Revenue
$692.0K-97.5%Net Income
$-31.77MEBITDA
$-29.06MFree Cash Flow
$-23.92MEPS (diluted)
$-0.07Shares Outstanding (diluted)
437.65M+321.3%Operating Expenses
$27.19MCash & Debt
$190.61MReturn of Capital
$0.00Revenue by Segment (annual)
$49.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $49.80M | $-50.34M | $-0.14 |
| 2024 | $31.08M | $-200.40M | $-0.63 |
| 2023 | $1.20M | $-177.12M | $-0.80 |
| 2022 | $139.0K | $-101.94M | $-0.62 |
| 2021 | $298.0K | $-87.76M | $-0.61 |
| 2020 | $24.00M | $-58.57M | $-0.63 |
| 2019 | $322.07M | $130.13M | $1.23 |
| 2018 | $63.21M | $-120.55M | $-1.14 |
| 2017 | $90.33M | $-129.05M | $-1.23 |
| 2016 | $83.34M | $-141.43M | $-1.36 |
| 2015 | $130.01M | $-4.68M | $-0.05 |
| 2014 | $22.85M | $-100.29M | $-1.31 |
| 2013 | $2.22M | $-104.13M | $-1.42 |
| 2012 | $1.09M | $-110.21M | $-1.58 |
Valuation
LXRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
166+232.50%Social Signal Score
Mentions (5)
- Newsfool.com·9d ago·Positive
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.
View source ↗ - Newsbenzinga.com·10d ago·Positive
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsseekingalpha.com·28d ago·Positive
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.06 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.06 vs $-0.05miss
- Thu, May 7$-0.00 vs $-0.04beat
- Thu, Mar 5$-0.04 vs $-0.07beat
- Thu, Nov 6$-0.04 vs $-0.07beat
- Wed, Aug 6$0.01 vs $-0.08beat
- Tue, May 13$-0.07 vs $-0.10beat
Estimates and results for LXRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LXRX officers and directors.
- Bought
- $723k
- Sold
- —
7 trades
0 trades
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
- Debbane Raymondbought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LXRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.